Wugen

Drug Discovery · Saint Louis, MO · Founded 2018 · Privately Held (backing)

Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. Wugen is based in Saint Louis, MO and was founded in 2018. It is valued at about $215 million as of Oct 2026, set by institutional fund marks, down 12% since its later-stage round in Aug 2025. It has raised $323 million across 2 recorded rounds; the latest was an $115 million Series C in Aug 2025.

PMV mark · valuation
$214.5M
Oct 2026
Since last round
-12%
Aug 2025
Total raised
$323.0M
Last round
Later Stage VC (Series C)
Aug 2025
What is Wugen worth?
$214.5MPrivateMarketView mark · Oct 2026

Down 12% since its later-stage round, Aug 2025 ($245.0M post-money).

Pro
The prices on Wugen
  • ·84 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Wugen funding history

2 rounds
DateRoundRaisedPost-money
Aug 2025Later Stage VC (Series C)$115.0M▮
Dec 2022Early Stage VC (Series B)$172.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Wugen valuation

Wugen is valued at approximately $215 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Aug 2025, at a $245 million post-money valuation; the current figure is down 12% since.

Recent activity

In the last 90 days, Wugen's record added 12 institutional fund marks (latest period Jul 2026).

How much has Wugen raised?

Wugen has raised $323 million across 2 recorded rounds since 2022. The largest was a $172 million Series B in Dec 2022; the most recent was an $115 million Series C in Aug 2025.

Institutional holders and vehicles

4 SEC-registered funds reported 84 fair-value marks on Wugen between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Convergent Therapeutics ($280 million), Artios ($260 million) and Edison Scientific ($255 million).

How Wugen's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Wugen, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →

Frequently asked about Wugen

What is Wugen worth?
Wugen is valued at $214.5M as of Oct 2026. Down 12% since its later-stage round, Aug 2025 ($245.0M post-money).
How much has Wugen raised?
Wugen has raised $323.0M in total funding across 2 recorded rounds.
When did Wugen last raise?
Wugen last raised in Aug 2025 (Later Stage VC (Series C)), raising $115.0M.